nelfinavir sold brand name viracept antiretroviral medication used treatment hivaids nelfinavir belongs class drugs known protease inhibitors pis like pis almost always used combination antiretroviral drugs nelfinavir orally bioavailable human immunodeficiency virus protease inhibitor ki nm widely prescribed combination hiv reverse transcriptase inhibitors treatment hiv patented approved medical use common side effects include insulin resistance hyperglycemia nelfinavir produce range adverse side effects flatulence diarrhea abdominal pain common ie experienced one one hundred patients fatigue urination rash mouth ulcers hepatitis less frequent effects experienced one one thousand one one hundred patients nephrolithiasis arthralgia leukopenia pancreatitis allergic reactions may occur rare less one one thousand patients nelfinavir inhibits maturation export herpes simplex kaposis sarcoma nelfinavir simple derivatives found inhibit production virulence factor streptolysin cytolysin produced human pathogen streptococcus nelfinavir related molecules exhibit detectable antibiotic activity also inhibit production biologically active molecules including plantazolicin antibiotic listeriolysin cytolysin clostridiolysin cytolysin nelfinavirs interaction profile similar protease inhibitors interactions occur level cytochrome isozymes nelfinavir metabolised nelfinavir taken food taking drug food decreases risk diarrhea side effect nelfinavir protease inhibitor inhibits proteases hiv protease aspartate protease splits viral protein molecules smaller fragments vital replication virus within cell also release mature viral particles infected cell nelfinavir competitive nm designed bind tightly cleaved due presence hydroxyl group opposed keto group middle amino acid residue mimic would otherwise sphenylcysteine protease inhibitors bind protease precise mode binding determines molecule inhibits protease way nelfinavir binds enzyme may sufficiently unique reduce crossresistanceclarification needed pis also pis inhibit proteases nelfinavir developed agouron pharmaceuticals part joint venture eli lilly agouron pharmaceuticals acquired warner lambert subsidiary pfizer marketed europe hoffmanla roche elsewhere viiv healthcarecitation needed us food drug administration fda approved therapeutic use march needed making twelfthcitation needed approved antiretroviral initial product launched proved largestcitation needed biotech launch history pharmaceutical industry achieving first full year sales exceeding needed agourons patent drug expired june medicines healthcare products regulatory agency european medicines put alert requesting recall drug circulation batches may contaminated potentially cancercausing chemicals since nelfinavir investigation potential use anticancer applied cancer cells culture vitro inhibit growth variety cancer types trigger cell death nelfinavir given laboratory mice tumors prostate brain could suppress tumor growth cellular level nelfinavir exerts multiple effects inhibit cancer growth two main ones appear inhibition aktpkb signaling pathway activation endoplasmic reticulum stress subsequent unfolded protein united states three dozen clinical trials conducted completed order determine whether nelfinavir effective cancer therapeutic agent trials nelfinavir used alone monotherapy fashion whereas others combined modes cancer therapy wellestablished chemotherapeutic agents radiation therapycitation needed april nelfinavir studied radiosensitizing agent part treatment advanced cervical httpsenwikipediaorgwikinelfinavir